 | Up a level |
Glatting, Frederik M; Hoppner, Jorge; Liew, Dawn P; van Genabith, Antonia; Spektor, Anna-Maria; Steinbach, Levin; Hubert, Alexander; Kratochwil, Clemens; Giesel, Frederik L; Dendl, Katharina; Rathke, Hendrik; Kauczor, Hans-Ulrich; Huber, Peter E; Haberkorn, Uwe; Röhrich, Manuel (2022). Repetitive Early 68Ga-FAPI PET Acquisition Comparing 68Ga-FAPI-02, 68Ga-FAPI-46, and 68Ga-FAPI-74: Methodologic and Diagnostic Implications for Malignant, Inflammatory/Reactive, and Degenerative Lesions. Journal of nuclear medicine, 63(12), pp. 1844-1851. Society of Nuclear Medicine 10.2967/jnumed.122.264069
Klenke, Frank Michael; Abdollahi, Amir; Bischof, Marc; Gebhard, Martha-Maria; Ewerbeck, Volker; Huber, Peter E; Sckell, Axel (2011). Celecoxib enhances radiation response of secondary bone tumors of a human non-small cell lung cancer via antiangiogenesis in vivo. Strahlentherapie und Onkologie, 187(1), pp. 45-51. Heidelberg: Springer-Medizin-Verlag 10.1007/s00066-010-2116-3
Klenke, Frank M; Abdollahi, Amir; Bertl, Elisabeth; Gebhard, Martha-Maria; Ewerbeck, Volker; Huber, Peter E; Sckell, Axel (2007). Tyrosine kinase inhibitor SU6668 represses chondrosarcoma growth via antiangiogenesis in vivo. BMC cancer, 7, p. 49. London: BioMed Central 10.1186/1471-2407-7-49
Klenke, Frank Michael; Gebhard, Martha-Maria; Ewerbeck, Volker; Abdollahi, Amir; Huber, Peter E; Sckell, Axel (2006). The selective Cox-2 inhibitor Celecoxib suppresses angiogenesis and growth of secondary bone tumors: an intravital microscopy study in mice. BMC cancer, 6, p. 9. London: BioMed Central 10.1186/1471-2407-6-9
